Spotlight Poster Discussion 5 – Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT
   
  Survivorship
PD5-01 Cardiovascular disease risk of breast cancer therapies: The pathways heart study
Greenlee H, Rillamas-Sun E, Iribarren C, Cheng R, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM, Shen H, Hershman DL, Kushi LH, Kwan ML. Fred Hutchinson Cancer Research Center, Seattle, WA; Kaiser Permanente Northern California, Oakland, CA; University of Washington School of Medicine, Seattle, WA; Herbert Irving Comprehensive Cancer Center, New York, NY.
PD5-02 Cardioprotective strategy for non-metastatic breast cancer patients receiving an anthracycline-based chemotherapy: subgroup analysis focused on impact of postoperative breast radiation therapy of the preplanned interim analysis of the phase 3 SAFE trial (NCT2236806)
Meattini I, Barletta G, Becherini C, Visani L, Martella F, Airoldi M, Amoroso D, Coltelli L, Bellini C, Stocchi G, Lorenzetti V, Orsatti C, Angelini L, Livi L. Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; CardioThoracic and Vascular Department, Careggi University Hospital, Florence, Italy; Oncology Department, Azienda USL Toscana Centro, Florence, Italy; Medical Oncology Unit 2, “Città della Salute e della Scienza” University Hospital, Turin, Italy; Medical Oncology Unit, Ospedale Versilia, Lido di Camaiore, Lucca, Italy; Medical Oncology Unit, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
PD5-03 Development of cardiometabolic risk factors following endocrine therapy: The pathways heart study
Greenlee H, Rillamas-Sun E, Iribarren C, Cheng R, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM, Shen H, Hershman DL, Kushi LH, Kwan ML. Fred Hutchinson Cancer Research Center, Seattle, WA; Kaiser Permanente Northern California, Oakland, CA; University of Washington School of Medicine, Seattle, WA; Herbert Irving Comprehensive Cancer Center, New York, NY.
PD5-04 Risk factors for long-term adjuvant chemotherapy toxicity using pre-treatment host factors and self-rated treatment bother (GP5) in a clinical trial population
Henry NL, Kim S, Hays RD, Diniz MA, Luu M, Tighiouart M, Cecchini RS, Yothers G, Rogatko A, Ganz PA. University of Michigan, Ann Arbor, MI; Cedars Sinai Medical Center, Los Angeles, CA; UCLA, Los Angeles, CA; University of Pittsburgh, Pittsburgh, PA.
PD5-05 Withdrawn
PD5-06 Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer
Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy A-S, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Córdoba O, Teixeira L, Clatot F, Punie K, Graffeo Galbiati R, Dieci MV, Pérez-Fidalgo A, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmaña J, Partridge AH, Azim HAJ, Demeestere I, Lambertini M. Hôpital Erasme, Fertility Clinic, and Université Libre de Bruxelles, Research Laboratory on Human Reproduction, Bruxelles, Belgium; Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical Sciences, General Surgery III-Breast Surgery, Fondazione IRCCS Policlinico San Matteo, and Department of Clinical Surgical Sciences, University of Pavia, Pavia, Italy; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Medical Oncology, Institut Curie, Paris, France; Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles, Bruxelles, Belgium; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gynecologic Oncology Department, European Institute of Oncology IRCCS, Milan, Italy; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France;Breast Oncology Unit Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center & Faculty of Medicine, Hebrew University, Jerusalem, Israel; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Oncology and Haematology, Azienda Ospedaliero Universitaria di Modena, Modena, Italy; Department of Surgery, Centre Léon Bérard, Lyon, France, and INSERM U1290 RESHAPE, Université Claude Bernard Lyon 1, Lyon, France; Cancer Genetics Unit, Bergonie Institute, Bordeaux, France; Medical Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; Gynecological Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Turin, Italy; Division of Medical Oncology, Department of Radiological, Oncological and Pathological Sciences, "La Sapienza" University of Rome, Rome, Italy; Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Oncology Division, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel; Department of Research and Breast Tumors, Instituto Nacional de Cancerologia and, Mexico City, Mexico; Obstetrics and Gynecology Department, Hospital Universitari Son Espases, Palma, Spain; Breast Disease Unit, Saint-Louis Hospital, APHP, Université de Paris, INSERM U976, Paris, France; Department of Medical Oncology, Centre Henri Becquerel, Rouen, France; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Breast Unit of Southern Switzerland (CSSI), Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Department of Surgery, Oncology and Gastroenterology, University of Padua and Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; Department of Medical Oncology, INCLIVA University Hospital of Valencia, CIBERONC, Valencia, Spain; Department of Medical Oncology, Breast Clinic, Cliniques Universitaires Saint-Luc, UCLouvain, Bruxelles, Belgium; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy; Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal; Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Medical Oncology, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France; Department of Genetics, Institut Curie, Paris, France; Data Centre, Institut Jules Bordet and Université Libre de Bruxelles, Bruxelles, Belgium; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova and Department of Medical Oncology, Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
PD5-07 Safety of assisted reproductive technologies before and after anticancer treatments in young women with breast cancer: A systematic review and meta-analysis
Arecco L, Blondeaux E, Bruzzone M, Ceppi M, Latocca MM, Boutros A, Marrocco C, Grazia Razeti M, Cosso M, Spinaci S, Condorelli M, Massarotti C, Del Mastro L, Demeestere I, Lambertini M. IRCCS Ospedale Policlinico San Martino, Genova, Italy; Ospedale Villa Scassi, Genova, Italy; Hôpital Erasme, Bruxelles, Belgium.
PD5-08 New and persistent sedative hypnotic use after adjuvant chemotherapy for breast cancer
Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Elkin EB, Melamed A, Wright JD, Hershman DL. Columbia University, New York, NY.
PD5-09 Work status changes and associated factors in a nation-wide sample of 1324 Norwegian long-term breast cancer survivors
Hoffart Bøhn S-K, Vandraas K, Kiserud CE, Dahl AA, Ewertz M, Hanne Lie C, Falk R, Valborg Reinertsen K. Oslo University Hospital, Oslo, Norway; University of Southern Denmark, Odense, Denmark; University of Oslo, Oslo, Norway.
PD5-10 Consequent job loss, return to work and multidimensional well-being after breast cancer treatment in working-age black and white women
Emerson MA, Reeve BB, Gilkey MB, Elmore SN, Bradley CJ, Troester MA. UNC Chapel Hill, Chapel Hill, NC; Duke University School of Medicine, Durham, NC; University of Colorado Comprehensive Cancer Center, Aurora, CO.
PD5-11 Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST)
O'Donnell EK, Shapiro YN, Comander A, Isakoff SJ, Moy B, Spring L, Wander S, Kuter I, Shin J, Younger J, Specht M, Kourniotis C, Sullivan C, Winters L, Horick N, Peppercorn J. Massachusetts General Hospital, Boston, MA.